top stories

Flag­ship ex­ecs take a les­son from na­ture to mas­ter ‘gene writ­ing,’ launch­ing a star-stud­ded biotech with big am­bi­tions to cure dis­ease

15 hours ago
Startups
Cell/Gene Tx

OWS shifts spot­light to drugs to fight Covid-19, hand­ing Re­gen­eron $450M to be­gin large scale man­u­fac­tur­ing in the US

18 hours ago
R&D
Coronavirus

Covid-19 roundup: Squab­bles with gov­ern­ment de­lay Mod­er­na’s PhI­II — re­ports; No­vavax se­cures largest Warp Speed ...

19 hours ago
Coronavirus

Latest

Boehringer In­gel­heim ties the knot with Num­ab on new an­ti­bod­ies; Ca­balet­ta inks pact with Ar­ti­san

15 hours ago
Protocols

AlloVir tests how much an an­tivi­ral biotech can reap in a pan­dem­ic stock mar­ket

15 hours ago
IPOs
R&D

Take­da’s post-merg­er deals con­tin­ue as OTC sub­sidiary is pre­pared for sale

16 hours ago
Deals

In­vestors give ail­ing Unum a lease on life and a whole new suite of ex­per­i­men­tal can­cer drugs

17 hours ago
Venture
Deals
see latest stream
People

Tes­la chief Elon Musk teams up with Covid-19 play­er Cure­Vac to build 'R­NA mi­cro­fac­to­ries'

5 days ago

Re­gen­eron co-founder George Yan­copou­los of­fers a com­bat­ive de­fense of the po­lice at a high school com­mence­ment. It ...

6 days ago

Elias Zer­houni dis­cuss­es ‘am­a­teur hour’ in DC, the de­struc­tion of in­fec­tious dis­ease R&D and how we need to prep ...

Last week
Startups

Out of jobs, a pair of ear­ly cell ther­a­py ex­ec­u­tives went to Seoul, came back with a new com­pa­ny, $70M and a plan to ...

Last week

Yale spin­out re-en­gi­neers an im­munother­a­py GSK, oth­ers once aban­doned

Last week

A vir­tu­al biotech in­cu­ba­tor is launch­ing with the help of Evotec and Sam­sara, look­ing for a few good sci­en­tists in ...

Last week
Deals

Pfiz­er re-ups on Mis­sion Ther­a­peu­tics col­lab­o­ra­tion, lead­ing a $15M round and grab­bing first dibs on DUBs

Yesterday

A boom­ing Drag­on­fly is tak­ing its TriN­KETs to Copen­hagen as the lat­est Bris­tol My­ers pact spurs ex­pan­sion plans — ...

Yesterday

An ex­pe­ri­enced biotech is stitched to­geth­er from transpa­cif­ic parts, with 265 staffers and a fo­cus on ‘new ...

6 days ago
IPOs

IPO bound? Ac­tu­al­ly, An­nex­on was al­ready prepped and primed to toss its S-1 to Wall Street as in­vestors ral­lied

Yesterday

Free­line nabs $120M, eyes IPO as its gene ther­a­py comes in­to fo­cus

Last week

The biotech IPO boom is be­com­ing ‘his­toric’ as four more throw their hats in

Last week

All of the news, delivered with full-text to your inbox. For professionals discovering, developing, and marketing biopharmaceutical drugs.

SUBSCRIBE NOW
Subscribe to Endpoints News

Premium storiesSee all

Which drug de­vel­op­ers of­fer Trump a quick, game-chang­ing ‘so­lu­tion’ as the pan­dem­ic roars back? Eli Lil­ly and ...

2 days ago
Bioregnum
Pharma

Day one: The dis­rup­tor-in-chief at Bridge­Bio in­vites Brent Saun­ders on­to the board

Last week
People
Bioregnum

What’s it take to raise $700M-plus for a biotech start­up? Steve Harr has some thoughts on that

2 weeks ago
Venture
Cell/Gene Tx

Two Bay Area up­starts out to de­liv­er on cell ther­a­py 2.0 join forces on a quest: pur­su­ing a Holy Grail in on­col­o­gy ...

3 weeks ago
Deals
Cell/Gene Tx

Don't missSee all

Cel­lec­tis slammed af­ter pa­tient dies and FDA slaps a hold on their tri­al for an off-the-shelf CAR-T for mul­ti­ple ...

Yesterday
Regulatory

A lit­tle biotech slaps back at a 'crim­i­nal' short at­tack, vow­ing to pur­sue a pros­e­cu­tion of their case

Yesterday
Pharma

Covid-19 roundup: Teamed up with NIH, Re­gen­eron launch­es PhI­II pre­ven­tion tri­al for an­ti­body cock­tail

Yesterday
Coronavirus

No­vavax snags Ben Machielse for CMC and pro­motes a trio of staffers; Mar­ty Du­vall lands an­oth­er CEO post at ...

5 days ago
Peer Review

Endpoints Standouts

The 20 un­der 40: In­side the next gen­er­a­tion of bio­phar­ma lead­ers

3 months ago
People
Special

Here are the 52 new drugs ap­proved by the FDA in 2019. Who won? Who lost? And who just sur­vived to 2020?

6 months ago
Special
Pharma

Spe­cial re­port: Twen­ty ex­tra­or­di­nary women in bio­phar­ma R&D who worked their way to the top

7 months ago
People
R&D

[Video] Cel­e­brat­ing tri­al fail­ures, chang­ing the cul­ture and al­ly­ing with Cal­i­for­nia dream­ers: R&D chief Hal Bar­ron ...

8 months ago

Peer review See all

Jun
26

In­ovio adds two to the lead­er­ship team; Adri­an Woolf­son is out at Sang­amo

Jun
19

Boehringer In­gel­heim nabs new US pres­i­dent and CEO; As­traZeneca vet hops aboard No­vavax as CMO

Jun
12

'Ris­ing star' CEO re­counts path from pre-med to break­through meds; Den­dreon taps Big Phar­ma vet Ja­son O'Neill as CEO

Jun
5

David Chang steps up to CEO spot at WuX­i's cell and gene ther­a­py CD­MO; David Meline is the new CFO at Mod­er­na

May
29

Sier­ra On­col­o­gy brings on for­mer Aim­mune CEO to the helm; Flag­ship woos ex-No­var­tis ex­ec Fab­rice Chouraqui

R&D channel feed

Yesterday

Sec­ond PhI­II study for Idor­si­a's sleep drug re­turns pos­i­tive re­sults, but al­so rais­es new ques­tions

Fol­low­ing a suc­cess­ful Phase III study in April show­cas­ing the safe­ty and po­ten­tial of its new sleep drug, Idor­sia post­ed some mixed news in the sec­ond Phase III study, but that won't ...

READ MORE

UP­DAT­ED: Im­munomedics spells out PFS ben­e­fit of Trodelvy in mTNBC, hunt­ing a full OK just weeks af­ter ac­cel­er­at­ed ...

Yesterday
Pharma

UP­DAT­ED: Ob­sE­va’s sec­ond uter­ine fi­broids PhI­II comes through, send­ing some in­vestors to the hills

Yesterday
latest in R&D

Bel­lus hit with a set­back as its PhII chron­ic cough drug flops on all 4 dos­es -- shares cre­mat­ed on Wall Street

Yesterday

De­vel­op­ment part­ners at MEI, Helsinn dump a high-risk PhI­II AML study af­ter con­clud­ing it would fail sur­vival goal

5 days ago

Io­n­is, lead­ing MS re­searcher throw an­ti­sense at a new type of brain cells

6 days ago
Cell/Gene Tx

Pfiz­er shares surge on pos­i­tive im­pact of their mR­NA Covid-19 vac­cine — part­nered with BioN­Tech — in an ear­ly-stage study

6 days ago
Coronavirus

Bolt Bio­ther­a­peu­tics nabs $93.5M to push Provenge in­ven­tor's new idea deep­er in the clin­ic

6 days ago
Venture
see latest stories

Pharma channel feed

5 days ago

No­var­tis pays $678M for kick­back scheme as Vas Narasimhan tries to dis­tance phar­ma gi­ant from shady be­hav­ior

No­var­tis has reached an­oth­er large set­tle­ment to re­solve mis­con­duct al­le­ga­tions, agree­ing to pay more than $678 mil­lion to set­tle claims that it had spent hun­dreds of mil­lions of dol­lars on ...

READ MORE

No­var­tis los­es biosim­i­lar ap­peal as court up­holds a 31-year mo­nop­oly by Am­gen's En­brel

5 days ago
Regulatory

New stan­dard of care? FDA hands Pfiz­er, Mer­ck KGaA an OK for Baven­cio in blad­der can­cer

6 days ago
Regulatory
latest in Pharma

On a roll, Mer­ck blazes through a new seg­ment of the bio­mark­er trail

Last week
Regulatory

Take­da takes a $200M hit af­ter No­var­tis is forced to yank its mar­ket­ing ap­pli­ca­tion for Xi­idra

Last week
Regulatory

Gilead opts for $3,120 US in­sur­er price for Covid-19 drug remde­sivir — but some say it should be free

Last week

DBV lays off em­ploy­ees, scales down pro­grams af­ter re­ceiv­ing no word from FDA

Last week
Regulatory

Sanofi preps an­oth­er round of lay­offs as new ex­ecs look to slim down the glob­al phar­ma in an on­go­ing re­or­ga­ni­za­tion — re­port

Last week
see latest stories

Coronavirus channel feed

6 days ago

Covid-19 has roiled clin­i­cal tri­al plans around the world, rais­ing con­cerns over the in­dus­try’s fu­ture on new drug ap­provals

Over the past 4 months, a group of an­a­lysts at Glob­al­Da­ta tracked 322 bio­phar­ma com­pa­nies — biotechs, phar­mas, CROs and such — re­port­ing on the trou­ble Covid-19 has caused for their ...

READ MORE

Covid-19 roundup: Vac­cines will need to beat place­bo by 50% to qual­i­fy for FDA OK; UK tri­al drops Kale­tra

Last week

WHO ACT-Ac­cel­er­a­tor pri­or­i­tizes glob­al vac­cine ap­proach

Last week
latest in Coronavirus

Covid-19 roundup: Temasek leads a $250M raise for BioN­Tech as first Covid-19 mR­NA vac­cine da­ta looms; Chi­na's mil­i­tary OKs first use of coro­n­avirus vac­cine

Last week

Covid-19 roundup: Mod­er­na en­lists Catal­ent as man­u­fac­tur­ing part­ner, se­cur­ing fill-fin­ish ca­pac­i­ty for the first 100M dos­es

Last week

Covid-19 roundup: An­tho­ny Fau­ci, Stephen Hahn tes­ti­fy in Con­gress; Chi­na's Sinopharm speeds in­to PhI­II vac­cine tri­al

Last week

Hahn tes­ti­fies on Covid-19 re­sponse, says FDA on tar­get to hit user fee goals

Last week
Regulatory

Law­mak­ers ask FDA to out­line Covid-19 vac­cine ap­proval process

2 weeks ago
Regulatory
see latest stories